29213-03-4

Basic information

• Product Name: 2,6-Dibromo-1,4-benzenediamine
• Synonyms: 2,6-Dibromo-1,4-benzenediamine;2,6-DibroMo-1,4-phenylenediaMine;2,6-Dibromobenzene-1,4-diamine
• CAS NO: 29213-03-4
• Molecular Formula: C₆H₆Br₂N₂
• Molecular Weight: 265.93
• Mol File: 29213-03-4.mol

Chemical Properties

• Melting Point: 136.0 to 140.0 °C
• Boiling Point: 332.5±37.0 °C(Predicted)
• Appearance: /
• Density: 2.104±0.06 g/cm3(Predicted)
• PKA: 3.71±0.10(Predicted)
• CAS DataBase Reference: 2,6-Dibromo-1,4-benzenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dibromo-1,4-benzenediamine(29213-03-4)
• EPA Substance Registry System: 2,6-Dibromo-1,4-benzenediamine(29213-03-4)

Safety Data

• Hazardous Substances Data: 29213-03-4(Hazardous Substances Data)

Usage

Usage

Dye or pigment in textiles, plastics, and inks

Color

Red

Solubility

Insoluble in water, soluble in organic solvents

Health risk

Potential skin sensitizer

Classification

Hazardous substance

Safety measures

Proper handling and usage to avoid risks to health and environment

Upstream product

• 827-94-1 2,6-dibromo-4-nitroaniline 
• 336624-08-9 acetic acid-(4-amino-2,6-dibromo-anilide) 
• 69521-00-2 2,6-dibromo-4-phenylazo-aniline 
• 60-09-3 aniline yellow 
• 122-80-5 N-acetyl-p-phenylenediamine 
• 84483-30-7 4-acetamido-2,6-dibromoaniline 

Downstream Products

• 855879-22-0 N-acetyl-sulfanilic acid-(4-amino-3,5-dibromo-anilide) 
• 82003-28-9 2,6-dibromo-N,N'-bisphenyl-benzoquinone diimine 
• 174628-56-9 sulfanilic acid-(4-amino-3,5-dibromo-anilide) 
• 1201798-82-4 N-(4-amino-3,5-dibromophenyl)-β-D-glucopyranosylamine 
• 1201798-83-5 N-(4-amino-3,5-dibromophenyl)-β-D-galactopyranosylamine 
• 444119-25-9 2,6-diiodo-N,N,N',N'-tetramethyl-p-phenylenediamine 
• 444119-24-8 2,6-dibromo-N,N,N',N'-tetramethyl-p-phenylenediamine 

Relevant articles and documents

Facile protocol for reduction of nitroarenes using magnetically recoverable CoM0.2Fe1.8O4 (M = Co, Ni, Cu and Zn) ferrite nanocatalysts

Transition metal doped cobalt ferrite (CoM0.2Fe1.8O4 (M = Co, Ni, Cu, Zn)) nanoparticles were fabricated using the sol-gel methodology. The obtained ferrite nanoparticles were annealed at 400 °C and characterized using Fourier transform infra-red spectroscopy (FT-IR), X-ray diffraction (XRD), high resolution transmission electron microscopy (HR-TEM), vibrating sample magnetometry (VSM) and energy dispersive X-ray (EDX) and scanning transmission electron microscopy (STEM). In the FT-IR spectra two bands in the range 1000-400 cm-1 were observed corresponding to the M-O bond in the tetrahedral and octahedral sites. XRD patterns confirmed the formation of a cubic spinel structure with a Fd3m space-group. HR-TEM analysis revealed a quasi-spherical shape with particle sizes in the range 20-30 nm for all the synthesized ferrite nanoparticles. The lattice inter-planar distances of 0.29, 0.25, 0.21 and 0.16 nm obtained from HR-TEM corresponding to the (2 2 0), (3 1 1), (4 0 0) and (5 1 1) lattice planes respectively were in complete agreement with the XRD data. The EDX-STEM confirmed the elemental composition as per the desired stoichiometric ratio. The catalytic efficiency of the synthesized ferrite samples was explored for the reduction of nitrophenols. Cu substituted cobalt ferrite nanoparticles (CoCu0.2Fe1.8O4) possessed excellent catalytic activity while CoM0.2Fe1.8O4 (M = Co, Ni and Zn) were inactive for the same. The substrate scope of the developed protocol was also evaluated for the reduction of various CH3-, NH2-, Br-, Cl- etc. substituted nitroaromatic compounds.

A covalent deprotection strategy for assembling supramolecular coordination polymers from metal-organic cages

A Cu4L4 metal-organic cage (MOC) composed of amine-protected ligands forms supramolecular coordination polymers (SCPs) upon covalent post-assembly deprotection. The amorphous SCPs form by virtue of aniline-copper coordination and possess a tunable porosit

The Suzuki–Miyaura Cross-Coupling as the Key Step in the Synthesis of 2-Aminobiphenyls and 2,2'-Diaminobiphenyls: Application in the Synthesis of Schiff Base Complexes of Zn

2-Nitrophenylboronic acids serve as interesting starting materials for the construction of biphenyl- and terphenyl-based amines if subjected to the Suzuki–Miyaura reaction. Unfortunately, these boronic acids suffer from low reactivity in Suzuki reactions, alongside their low stability in the presence of Pd. Herein, a general method for the construction of 2-nitro-substituted bi- and terphenyls is presented, with special emphasis on the synthesis of 2-amino-2'-nitrobi- and terphenyls. Comparisons are made with other boronic acids that have some of the aforementioned issues. Finally, the application of the obtained 2-amino-2'-nitrobi- and terphenyls as starting materials for the synthesis of bi- and terphenyl based di- and triamines is encountered for, with emphasis on the use of these amines as precursors for Schiff base ligands. In addition, the synthesis of some Zn complexes of these ligands is presented.

Synthesis, structural characterization and computational study of NLO-responsive chromophores and second-order coefficients of thermally crosslinked polymers

This paper emphasizes the preparation of nonlinear optical (NLO) responsive chromophores and their corresponding polymers. Initially, the carboxyl acid group-based precursors of the chromophores containing strong acceptors such as nitro-substituted thiazo

Investigation of 2,6-disubstituted N,N,N′,N′-tetramethyl-p-phenylenediamines as precursors/building blocks for molecular magnets

The synthesis of 2,6-disubstituted N,N,N′,N′-tetramethyl-p-phenylenediamines (R = Cl, Br, I, CN, or C≡CSi(CH3)3), potential precursors/building blocks for molecular magnets, is presented. In addition to standard methods (1

Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of oncoses, and their preparation. Exemplary compounds are: (a) 4-(5-indolylamino)-6-morpholinopyrimido[5,4-d]pyrimidine; (b) 4-(5-indolylamino)-6-[trans-(4-hydroxycyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (c) 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-(morpholinocarbonylmethyl)-1-piperazinyl]pyrimido[5,4-d]pyrimidine; (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-morpholinyl)amino]pyrimido[5,4-d]pyrimidine; (e) 4-[(3-chloro-4-fluorophenyl)amino]-6-(4-picolylamino)pyrimido[5,4-d]pyrimidine; (f) 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-trifluoroacetyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine; (g) 4-[(3-chloro-4-fluorophenyl)amino]-6-(endo-tropinylamino)pyrimido[5,4-d]pyrimidine; and, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-(exo-tropinylamino)pyrimido[5,4-d]pyrimidine.

Pyrimido?5,4-D!pyrimidines, medicaments comprising these compounds, their use and processes for their preparation

The present invention relates to pyrimido?5,4-d!pyrimidines of the general formula STR1 in which Ra to Rc are as defined herein, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibiting action on signal transduction mediated by tyrosine kinases, their use for the treatment of diseases, in particular tumor diseases.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.